Most antiarrhythmic drugs fulfil the formal requirements for rational use of therapeutic drug
monitoring, as they show highly variable plasma concentration profiles at a given dose and …

Measurement of drug levels is becoming increasingly popular to optimise the dosage of
various drugs. In the case of antiarrhythmic drugs, the narrow therapeutic margin of most of …

Therapeutic drug monitoring has come of age in clinical medicine and, in particular, its use
with antiarrhythmic agents has flourished. The classic indications for the use of therapeutic …

Plasma concentration monitoring of antiarrhythmic agents is valuable, but it is often misused
or overemphasized in therapeutic decision-making. There are strict requirements for its …

The clinical use of plasma concentrations of antiarrhythmic agents suffers from important
limitations. Any factor changing the protein binding capacity affects the free, clinically active …

Lo" lO\lC'lhcrapcutlc doSt'ratIO.:!. l'nC\IX'clcd\arlllblllt~ In pharmacokmellcs. 3. ThcralX'ulic
end-point nOI casll~ measured (('. g proph~ 13\, 5 of St'rlOUS and rarc c, cnIS).-\nllarrh) …

It is widely accepted that the effects (both cardiac and extracardiac) of antiarrhythmic drugs
are modulated by their concentration at some unidentified active site, and that the drug …

Five commonly used antiarrhythmic agents are examined with regard to their
pharmacokinetics, pharmacology, electrophysiology, and clinical utility. The effective …

The therapeutic and toxic effects of antiar-rhythmic drugs depend on drug concentration at
the sites of action. Since a specific receptor for most antiarrhythmic drugs has not been …

Table I lists pharmacokinetic parameters for eight of the drugs discussed as well as for
quinidine, procainamide, and lidocaine. Data for two of the new agents, bretylium 41 and …